À des fins de recherche uniquement

Anticorps Recombinant de lapin anti-TDP-43



Numéro de catalogue:80002-1-RR

Phare

3 Publications

Informations de base

Numéro de catalogue:

80002-1-RR

Taille:

100ul , Concentration: 250 $\mu g/ml$ by

Nanodrop:

Lapin IgG Immunogen Catalog Number:

AG1231

Applications

Applications testées:

FC, IF, IP, WB, ELISA Demandes citées: IF, IHC, IP, WB

Spécificité de l'espèce: Humain, rat, souris

Espèces citées: Humain, souris Numéro d'acquisition GenBank:

BC001487

Identification du gène (NCBI):

Nom complet:

TAR DNA binding protein

MW calculé 43 kDa

MW observés: 43 kDa

Contrôles positifs:

WB: cellules HeLa, cellules C6, cellules K-562, cellules

Méthode de purification:

CloneNo.:

16A22

Purification par protéine A

Dilutions recommandées:

WB 1:5000-1:50000 IF 1:50-1:500

IF: cellules SH-SY5Y, cellules HeLa, cellules HepG2,

tissu cérébral de rat

Informations générales

The TARDBP gene encodes the TDP-43 protein, initially found to repress HIV-1 transcription by binding TAR DNA. TDP-43 has since been shown to bind RNA as well as DNA, and have multiple functions in transcriptional repression, translational regulation and pre-mRNA splicing. For instance, it is reported to regulate alternate splicing of the CTFR gene. In 2006 Neumann et al. found that hyperphosphorylated, ubiquitinated and/or cleaved forms of TDP-43, collectively known as pathological TDP-43, play a major role in the disease mechanisms of ubiquitin-positive, tauand alpha-synuclein-negative frontotemporal dementia (FTLD-U) and in amyotrophic lateral sclerosis (ALS). $Protein tech's \, 80002-1-RR \, is \, a \, rabbit \, recombinant \, TDP-43 \, antibody \, recognizing \, N-terminal \, TDP-43. \, It \, recognizes \, the \, r$ intact 43 kDa protein as well as all posttranslationally modified and truncated forms in multiple applications. Various forms of TDP-43 exist, including 18-35 kDa of cleaved C-terminal fragments, 45-50 kDa phospho-protein, 55 kDa glycosylated form, 75 kDa hyperphosphorylated form, and 90-300 kDa cross-linked form. (PMID: 17023659, 19823856, 21666678, 22193176) Recently TDP-43 has been reported to be overexpressed in triple negative breast cancer (TNBC) and it may be a potential target for TNBC diagnosis and drug design. (PMID: 29581274)

80002-1-RR antibody works well in IF experiment.

Publications notables

Autrice	Pubmed ID	Journal	Application
Shi-Shi Jiang	36926731	Neural Regen Res	WB,IF
Julie Dewisme	37428895	J Neuropathol Exp Neurol	IHC
Donovan Worrall	37359785	F1000Res	WB,IF,IP

Stockage

Stockage:

Stocker à -20°C. Stable pendant un an après l'expédition.

Tampon de stockage

PBS avec azoture de sodium à 0,02 % et glycérol à 50 % pH 7,3 L'aliquotage n'est pas nécessaire pour le stockage à -20C

*** Les 20ul contiennent 0,1% de BSA.


For technical support and original validation data for this product please contact:

T: 1 (888) 4PTGLAB (1-888-478-4522) (toll free in USA), or 1(312) 455-8498 (outside USA)


E: proteintech@ptglab.com W: ptglab.com

This product is exclusively available under Proteintech Group brand and is not available to purchase from any other manufacturer.


Données de validation sélectionnées




Various cell lysates were subjected to SDS PAGE followed by western blot with 80002-1-RR (TDP-43 antibody) at dilution of 1:12000 incubated at room temperature for 1.5 hours.




HAP1 (WT and TARDBP KO) lysates prepared with NP-40 buffer, 50 µg protein loaded, 80002-1-RR incubated at 1:1000 at 4°C overnight in 5% milk in TBST. Ponceau stained transfers shown on right. Data provided by YCharOS, an open science company with a mission to validate commercial antibodies to improve scientific reproducibility and transparency.




WB result of TDP-43 antibody (80002-1-RR; 1:80000; incubated at room temperature for 1.5 hours) with sh-Control and sh-TDP-43 transfected HeLa cells.



HAP1 lysates prepared and IP of TARDBP performed using 2.0 µg of 80002-1-RR coupled to protein A-Sepharose beads. The Ponceau stained transfers of each blot are shown. Data provided by YCharOS, an open science company with a mission to validate commercial antibodies to improve scientific reproducibility and transparency.




Immunofluorescent analysis of (4% PFA) fixed rat brain tissue using 80002-1-RR (TDP-43 antibody) at dilution of 1:200 and CoraLite488-Conjugated AffiniPure Goat Anti-Rabbit IgG(H+L).




Immunofluorescent analysis of (4% PFA) fixed SH-SY5Y cells using TDP-43 antibody (80002-1-RR, Clone: 16A22) at dilution of 1:200 and Coralite® 488-Conjugated AffiniPure Goat Anti-Rabbit IgG(H+L). Red: staining with Coralite555-Phalloidin.



Immunofluorescent analysis of (4% PFA) fixed HeLa cells using TDP-43 antibody (80002-1-RR, Clone: 16A22) at dilution of 1:400 and CoraLite®488-Conjugated Affini Pure Goat Anti-Rabbit 1gG(H+L), CL594-Phalloidin (red).



HAP1 WT cells (yellow outline) and TARDBP KO cells (red outline) labelled with a green or a far red fluorescence dye, respectively. Cells fixed with 4% PFA and stained with 80002-1-RR at 1:200 plus DAPI. Bars = 10 µm. Data provided by YCharOS, an open science company with a mission to validate commercial antibodies to improve scientific reproducibility and transparency.



1X10^6 HeLa cells were intracellularly stained with 0.4 ug Anti-Human TDP-43 (for IF/FC) (80002-1-RR, Clone:16A22) and CoraLite® 488-Conjugated AffiniPure Goat Anti-Rabbit IgG(H+L) at dilution 1:1000 (red), or 0.4 ug Control Antibody. Cells were fixed and permeabilized with Transcription Factor Staining Buffer Kit (PF00011).